Inflectra to be first 'substitutable' biosimilar in Australia
This article was originally published in SRA
Executive Summary
Australia's Pharmaceutical Benefits Advisory Committee has recommended that Hospira's biosimilar Inflectra (infliximab) - which has only just been approved as the country's first biosimilar monoclonal antibody - should be listed on the Pharmaceutical Benefits Scheme1,2. And in a highly controversial move, the PBAC has also said that Inflectra should be 'a'-flagged, meaning that it can be substituted by pharmacists for the originator drug, Johnson & Johnson's Remicade.
You may also be interested in...
Australia's Biosimilar Substitution Policy Under Fire As Etanercept Product Is 'A'-Flagged
Australia's new policy of 'a'-flagging biosimilars, or allowing them to be substituted for the prescribed originator drug in the pharmacy, is coming under fire amid concerns that the move is overly driven by economic considerations and may not be the most appropriate way of improving patient access to cheaper biologic medicines.
Australia's Biosimilar Substitution Policy Under Fire As Etanercept Product Is 'A'-Flagged
Australia's new policy of 'a'-flagging biosimilars, or allowing them to be substituted for the prescribed originator drug in the pharmacy, is coming under fire amid concerns that the move is overly driven by economic considerations and may not be the most appropriate way of improving patient access to cheaper biologic medicines.
Denmark Planning To Impose Drug Stockpiling Obligations From July
A new bill is intended to address the increase in medicine supply problems in Denmark in recent years.